Eagle Pharmaceuticals (EGRX) Misses Q1 EPS by 9c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Eagle Pharmaceuticals (EGRX) Misses Q1 EPS by 9c

Eagle Pharmaceuticals, Inc. Reports First Quarter 2015 Results

May 12, 2015 6:50 AM EDT

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eagle Pharmaceuticals, Inc. (Eagle or the Company) (Nasdaq: EGRX) today announced its financial results for the three-month period ended March 31, 2015. Highlights of and subsequent to the first quarter of 2015 include:

Entered into an Exclusive License Agreement (the License Agreement) and a Settlement and License Agreement (the Settlement Agreement) for our bendamustine hydrochloride (HCl) rapid infusion product (the rapid infusion product) with Cephalon, Inc., a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA). Under the terms of the License... More